Kupando Raises €10M in Series A Extension to Advance Innate Immunity Drug

Why It Matters

The funding moves Kupando from pre‑clinical development into human trials, testing a novel innate‑immunity platform that could broaden treatment options for cancer and antimicrobial‑resistant infections.

Key Takeaways

• Series A raised to €23 million for Phase 1b trial
• Dual TLR4/7 agonist targets solid tumours, infections
• Innate immunity approach offers tissue‑agnostic, broad patient pool
• Carma Fund joins, signaling confidence amid tight financing
• Phase 1b study funded by new capital and German ministry

Pulse Analysis

Kupando’s €10 million Series A extension underscores a growing appetite for innovative immunotherapies that diverge from the adaptive‑focused checkpoint era. By securing €23 million total, the Berlin‑area firm aligns with a wave of European biotech financing that favours platforms with clear clinical pathways. The fresh capital not only funds a Phase 1b study of KUP101 in solid tumours but also bolsters pre‑clinical programmes targeting antimicrobial‑resistant pathogens, a sector traditionally starved of investment.

The scientific core of KUP101 lies in its dual activation of Toll‑Like Receptor 4 and 7, delivering a coordinated innate‑immune surge. This “trained immunity” reprograms myeloid cells epigenetically, granting prolonged heightened responsiveness. Unlike adaptive‑immune checkpoint inhibitors, the approach is tissue‑agnostic, potentially serving a wide spectrum of tumour types and infection sites. Co‑encapsulation in a liposomal carrier enhances delivery efficiency, positioning the drug as a versatile platform rather than a single‑indication candidate.

Beyond oncology, KUP101’s mechanism tackles the looming antimicrobial‑resistance crisis by empowering the body’s own defenses rather than directly targeting pathogens. Investors such as Carma Fund see this as a differentiated, high‑impact opportunity in a market where conventional antibiotics face dwindling pipelines. Successful Phase 1b outcomes could catalyse partnerships with larger pharma, accelerate regulatory pathways, and set a precedent for innate‑immunity‑based therapeutics across multiple disease areas, reshaping how the industry approaches both cancer and infectious disease treatment.

Deal Summary

Kupando announced an additional €10 million in Series A financing, bringing its total Series A to €23 million. The round was led by Remiges Ventures and co‑led by LifeCare Partners, with participation from Brandenburg Kapital, High‑Tech Gründerfonds, Ventura Biomed Investors and new investor Carma Fund. The funds will support a Phase 1b trial of its dual TLR agonist KUP101 for solid tumours and drug‑resistant infections.